The renal endothelium in diabetic nephropathy

Renal Failure

Volumn 35, Issue 4, 2013, Pages 592-599

  Eleftheriadis, Theodoros ^a   Antoniadi, Georgia ^a   Pissas, Georgios ^a   Liakopoulos, Vassilios ^a   Stefanidis, Ioannis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Albuminuria; Diabetic nephropathy; Endothelial dysfunction; Fenestration; Fibrosis; Glomerular filtration rate; Glycocalyx; Neoangiogenesis

Indexed keywords

VASCULOTROPIN A;

ANGIOGENESIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM; ENDOTHELIUM CELL; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; GLYCOCALYX; HUMAN; HYPERGLYCEMIA; KIDNEY CELL; KIDNEY FIBROSIS; MEDIATOR; MICROALBUMINURIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL ENDOTHELIUM; REVIEW; ULTRAFILTRATION;

DIABETIC NEPHROPATHIES; ENDOTHELIUM; HUMANS; KIDNEY; KIDNEY GLOMERULUS;

EID: 84876359508     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.773836     Document Type: Review

References (117)

1. Burrows NR, Li Y, Geiss LS. Incidence of treatment for endstage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care. 2010;33:73-77
2. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc. 2001;286:421-426
3. Bearer EL, Orci L. Endothelial fenestral diaphragms: A quickfreeze, deep-etch study. J Cell Biol. 1985;100:418-428
4. Ichimura K, Stan RV, Kurihara H, et al. Glomerular endothelial cells form diaphragms during development and pathologic conditions. J Am Soc Nephrol. 2008;19:1463-1471
5. Kanwar YS, Sun L, Xie P, et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011;6:395-423
6. Brosius FC, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatr Nephrol. 2005;20:447-451
7. Chung SS, Ho EC, Lam KS, et al. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol. 2003;14:S233-S236
8. Quest AF, Ghosh S, Xie WQ, et al. DAG second messengers: Molecular switches and growth control. Adv Exp Med Biol. 1997;400A:297-303
9. Parker PJ, Murray-Rust J. PKC at a glance. J Cell Sci. 2004;117:131-132
10. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl. 2000;77: S13-S18
11. Thomas MC, Baynes JW, Thorpe SR, et al. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005;6:453-474
12. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol. 2007;292:F905-F911
13. Whiteside CI, Dlugosz JA. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol. 2002;282:F975-F980
14. Thallas-Bonke V, Lindschau C, Rizkalla B, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT- 711 via a protein kinase C-alpha-dependent pathway. Diabetes. 2004;53:2921-2930
15. Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1383-1395
16. Forbes JM, Cooper ME, Oldfield MD, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14:S254-S258
17. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol. 2005;16:2976-2984
18. Sato M, Muragaki Y, Saika S, et al. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest. 2003;112:1486-1494
19. Anderson SS, Tsilibary EC, Charonis AS. Nonenzymatic glycosylation- induced modifications of intact bovine kidney tubular basement membrane. J Clin Invest. 1993;92:3045- 3052
20. Haitoglou CS, Tsilibary EC, Brownlee M, et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem. 1992;267:12404-12407
21. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14:439-447
22. Menne J, Park JK, Boehne M, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alphadeficient diabetic mice. Diabetes. 2004;53:2101-2109
23. Nakagawa T, Segal M, Croker B, et al. A breakthrough in diabetic nephropathy: The role of endothelial dysfunction. Nephrol Dial Transplant. 2007;22:2775-2777
24. Yamagishi S, Fukami K, Ueda S, et al. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952-959
25. Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase Cdependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: Role of vascular NAD(P)H oxidase. J Am Soc Nephrol. 2003;14:S227-S232
26. Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: Potential relevance in diabetic nephropathy. J Am Soc Nephrol. 2003;14:S221-S226
27. Kunisaki M, Bursell SE, Umeda F, et al. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes. 1994;43:1372- 1377
28. Maassen JA, T Hart LM, Van Essen E, et al. Mitochondrial diabetes: Molecular mechanisms and clinical presentation. Diabetes. 2004;53(Suppl. 1):S103-S109
29. Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes. 2004;53:1412-1417
30. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790
31. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol. 2000;278:F676-F683
32. Simon AR, Rai U, Fanburg BL, et al. Activation of the JAKSTAT pathway by reactive oxygen species. Am J Physiol. 1998;275:C1640-C1652
33. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810- 17814
34. Nath KA, Grande J, Croatt A, et al. Redox regulation of renal DNA synthesis, transforming growth factor-beta1 and collagen gene expression. Kidney Int. 1998;53:367-381
35. Pautz A, Franzen R, Dorsch S, et al. Cross-talk between nitric oxide and superoxide determines ceramide formation and apoptosis in glomerular cells. Kidney Int. 2002;61:790-796
36. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium. 2004;11:89-97
37. Brodsky SV, Gao S, Li H, et al. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol. 2002;283: H2130-H2139
38. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol. 1997;29: 8-15
39. Singh R, Singh AK, Alavi N, et al. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol. 2003;14:873-880
40. Touyz RM, Chen X, Tabet F, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II. Circ Res. 2002;90:1205-1213
41. Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol. 1999;10:730-737
42. Gilbert RE, Cox A, Wu LL, et al. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of ACE inhibition. Diabetes. 1998;47:414-422
43. Gruden G, Zonca S, Hayward A, et al. Mechanical stretchinduced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes. 2000;49:655-661
44. Gruden G, Setti G, Hayward A, et al. Mechanical stretch induces monocyte chemoattractant activity via an NFkappaB- dependent monocyte chemoattractant protein-1- mediated pathway in human mesangial cells: Inhibition by rosiglitazone. J Am Soc Nephrol. 2005;16:688-696
45. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol. 2001;281: F579-F596
46. Lane PH, Steffes MW, Mauer SM. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes. 1992;41:581-586
47. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia. 1999; 42:1341-1344
48. Steffes MW, Schmidt D, McCrery R, et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001;59:2104-2113
49. Dalla Vestra M, Masiero A, Roiter AM, et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 2003;52:1031-1035
50. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: Albuminuria and increased microvascular permeability. J Pathol. 2012;226:562-574
51. Hjalmarsson C, Johansson BR, Haraldsson B. Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc Res. 2004;67:9-17
52. Friden V, Oveland E, Tenstad O, et al. The glomerular endothelial cell coat is essential for glomerular filtration. Kidney Int. 2011;79:1322-1330
53. Jeansson M, Bjorck K, Tenstad O, et al. Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol. 2009;20:114-122
54. Meuwese MC, Broekhuizen LN, Kuikhoven M, et al. Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein E-deficient mice. PLoS One. 2010;5:e14262
55. Singh A, Friden V, Dasgupta I, et al. High glucose causes dysfunction of the human glomerular endothelial glycocalyx. Am J Physiol Renal Physiol. 2011;300:F40-F48
56. Kuwabara A, Satoh M, Tomita N, et al. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia. 2010;53:2056-2065
57. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006;55:1127-1132
58. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53:2646-2655
59. Seyer-Hansen K. Renal hypertrophy in experimental diabetes mellitus. Kidney Int. 1983;23:643-646
60. Seyer-Hansen K. Renal hypertrophy in streptozotocin-diabetic rats. Clin Sci Mol Med Suppl. 1976;51:551-555
61. Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia. 1993;36:189-194
62. Osterby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications. 1987;1:122-127
63. Wehner H, Nelischer G. Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats. Virchows Arch A Pathol Anat Histopathol. 1991;419:231-235
64. Nakagawa T, Kosugi T, Haneda M, et al. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009;58:1471-1478
65. Kanesaki Y, Suzuki D, Uehara G, et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis. 2005;45:288-294
66. MinW, Yamanaka N. Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy. Virchows Arch A Pathol Anat Histopathol. 1993;423:201-207
67. Mauer SM, Steffes MW, Ellis EN, et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74: 1143-1155
68. Hohenstein B, Hausknecht B, Boehmer K, et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006;69:1654-1661
69. Tremolada G, Del Turco C, Lattanzio R, et al. The role of angiogenesis in the development of proliferative diabetic retinopathy: Impact of intravitreal anti-VEGF treatment. Exp Diabetes Res. 2012;2012:728325
70. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48:2229-2239
71. Baelde HJ, Eikmans M, Doran PP, et al. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis. 2004;43:636-650
72. Baelde HJ, Eikmans M, Lappin DW, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 2007;71:637-645
73. Lindenmeyer MT, Kretzler M, Boucherot A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 2007;18:1765-1776
74. Ichinose K, Maeshima Y, Yamamoto Y, et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005;54:2891-2903
75. Ku CH, White KE, Dei Cas A, et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes. 2008;57:2824-2833
76. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001;12:993- 1000
77. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716
78. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136
79. Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol. 2011;7:36-44
80. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol. 2003;284:F1121- F1137
81. Chiarelli F, Cipollone F, Romano F, et al. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: Relation to glomerular hyperfiltration. Diabetes. 2000;49:1258-1263
82. Zanchi A, Moczulski DK, Hanna LS, et al. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 2000;57:405-413
83. Ezzidi I, Mtiraoui N, Mohamed MB, et al. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. J Diabetes Complications. 2008;22:331-338
84. Shin Shin Y, Baek SH, Chang KY, et al. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract. 2004;65:257-265
85. Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18:539-550
86. Sugimoto H, Shikata K, Matsuda M, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia. 1998;41: 1426-1434
87. Hohenstein B, Hugo CP, Hausknecht B, et al. Analysis of NOsynthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant. 2008;23:1346-1354
88. Kosugi T, Heinig M, Nakayama T, et al. Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am J Pathol. 2009;174:1221-1229
89. Nakagawa T, Sato W, Sautin YY, et al. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol. 2006;17:736-745
90. Sato W, Kosugi T, Zhang L, et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest. 2008;88:949-961
91. Li Q, Verma A, Han PY, et al. Diabetic eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci. 2010;51:5240-5246
92. Nakayama T, Sato W, Yoshimura A, et al. Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney. Am J Pathol. 2010;176:2198-2208
93. Kosugi T, Heinig M, Nakayama T, et al. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am J Pathol. 2010;176:619-629
94. Toyoda M, Najafian B, Kim Y, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007;56:2155-2160
95. Weil EJ, Lemley KV, Mason CC, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int. 2012;82:1010-1017
96. Satchell SC. The glomerular endothelium emerges as a key player in diabetic nephropathy. Kidney Int. 2012;82:949-951
97. Lafayette RA, Druzin M, Sibley R, et al. Nature of glomerular dysfunction in pre-eclampsia. Kidney Int. 1998;54:1240-1249
98. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683
99. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658
100. Kim KA, Shin YJ, Kim JH, et al. Dysfunction of endothelial progenitor cells under diabetic conditions and its underlying mechanisms. Arch Pharm Res. 2012;35:223-234
101. Dessapt C, Karalliedde J, Hernandez-Fuentes M, et al. Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care. 2010;33:875-877
102. + cells are associated with progression of diabetic nephropathy. Diabet Med. 2009;26:171-173
103. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781-2786
104. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006;26: 2140-2146
105. Marrotte EJ, Chen DD, Hakim JS, et al. Manganese superoxide dismutase expression in endothelial progenitor cells accelerates wound healing in diabetic mice. J Clin Invest. 2010;120:4207- 4219
106. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: Restoration by the peroxisome proliferator-activated receptorgamma agonist rosiglitazone. Circulation. 2007;116:163-173
107. Ma FX, Zhou B, Chen Z, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res. 2006;47: 1227-1237
108. Desouza CV, Hamel FG, Bidasee K, et al. Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction. Diabetes. 2011;60:1286-1294
109. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000;97:8015-8020
110. Wang S, de Caestecker M, Kopp J, et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol. 2006;17:2504-2512
111. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233:109-122
112. Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008;19:2282-2287
113. Li J, Qu X, Yao J, et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes. 2010;59:2612-2624
114. Chang FC, Chou YH, Chen YT, et al. Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis. J Formos Med Assoc. 2012;111:589-598
115. Rojas A, Chang FC, Lin SL, et al. The role played by perivascular cells in kidney interstitial injury. Clin Nephrol. 2012;77:400-408
116. Schrimpf C, Xin C, Campanholle G, et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol. 2012;23:868-883
117. Fligny C, Duffield JS. Activation of pericytes: Recent insights into kidney fibrosis and microvascular rarefaction. Curr Opin Rheumatol. 2013;25:78-86